Was it a lack of regulatory oversight or an isolated case to be learned from and put in the past? A year after the demise of Able Labs, FDA is still considering its role in the fiasco, in which research chemists conspired to falsify test data on key products in development. Sunday's New Jersey Star Ledger sheds some light on the Agency's current soul-searching. (You may have to input your zip code to read.)
-- PWT
